{"id":742693,"date":"2023-03-27T07:05:41","date_gmt":"2023-03-27T11:05:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/"},"modified":"2023-03-27T07:05:41","modified_gmt":"2023-03-27T11:05:41","slug":"aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/","title":{"rendered":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WAYNE, Pa., March  27, 2023  (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.<\/p>\n<p>A webcast of the fireside chat may be accessed through the \u201cEvents\u201d page of the \u201cInvestors\u201d section of Aclaris\u2019 website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.<\/p>\n<p>\n        <strong>About Aclaris Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&amp;D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.<\/p>\n<p>\n        <strong>Aclaris Therapeutics Contact:<\/strong>\n      <\/p>\n<p>Robert A. Doody Jr.<br \/>Vice President, Investor Relations<br \/>484-639-7235<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UfvDEJK1A2AqrcU9ZTKX3WS4T9Xzzh2VYp6H2WsBYm9J1YNE_PiuXbqycGo7zB8PtCviYHehYfcFpZE4EnB8gVhyoEfCmYDexesJBEdFshg=\" rel=\"nofollow noopener\" target=\"_blank\">rdoody@aclaristx.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Yjg2MThiYWUtMjcwYS00MmIyLTgxY2UtZjlmMmZiNzM5NmU2LTEwMzE3NTU=\/tiny\/Aclaris-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET. A webcast of the fireside chat may be accessed through the \u201cEvents\u201d page of the \u201cInvestors\u201d section of Aclaris\u2019 website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742693","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET. A webcast of the fireside chat may be accessed through the \u201cEvents\u201d page of the \u201cInvestors\u201d section of Aclaris\u2019 website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients &hellip; Continue reading &quot;Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T11:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference\",\"datePublished\":\"2023-03-27T11:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"wordCount\":185,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"name\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\",\"datePublished\":\"2023-03-27T11:05:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","og_description":"WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) &#8212; Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET. A webcast of the fireside chat may be accessed through the \u201cEvents\u201d page of the \u201cInvestors\u201d section of Aclaris\u2019 website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients &hellip; Continue reading \"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-27T11:05:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference","datePublished":"2023-03-27T11:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/"},"wordCount":185,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/","name":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=","datePublished":"2023-03-27T11:05:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTE4NyM1NDgwODMwIzIwMjAxODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune &amp; Inflammatory Disease Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742693"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}